TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial)-Reference-Cited by-同舟云学术

TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial)

Published:2019-01 Issue: Volume:106 Page:78-88
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Ioka Tatsuya,Ueno Makoto,Ueno Hideki,Park Joon Oh,Chang Heung-Moon,Sasahira Naoki,Kanai Masashi,Chung Ik Joo,Ikeda Masafumi,Nakamori Shoji,Mizuno Nobumasa,Omuro Yasushi,Yamaguchi Taketo,Hara Hiroki,Sugimori Kazuya,Furuse Junji,Maguchi Hiroyuki,Furukawa Masayuki,Fukuzawa Kengo,Kim Jun-Suk,Yukisawa Seigo,Takeuchi Masahiro,Okusaka Takuji,Boku Narikazu,Hyodo Ichinosuke

Funder

Taiho Pharmaceutical Co., Ltd.

Taiho Pharmaceutical Co. Ltd

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference14 articles.

1. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;Burris;J Clin Oncol,1997

2. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine;Von Hoff;N Engl J Med,2013

3. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;Conroy;N Engl J Med,2011

4. NCCN clinical practice guidelines in oncology,2017

5. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial;Oettle;J Clin Oncol,2014

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer;Scientific Reports;2024-05-30

2. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: A multicenter retorospective ovservational study (NAPOLEON-2);2024-03-18

3. The Natural Product Parthenolide Inhibits Both Angiogenesis and Invasiveness and Improves Gemcitabine Resistance by Suppressing Nuclear Factor κB Activation in Pancreatic Cancer Cell Lines;Nutrients;2024-02-29

4. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: A multicenter retrospective observational study (NAPOLEON-2);2023-12-06

5. C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel;Scientific Reports;2023-05-31